SAN FRANCISCO (GenomeWeb) – After receiving approval from the China Food and Drug Administration for a sequencing-based HPV test that relies on self-sampling technology for screening women for cervical cancer, BGI is targeting the test at women in rural areas of China.  

Na Liu, BGI Genomics' vice president, said that the CFDA approved the test in June to run on the BGISEQ-100, one of BGI's internally developed CFDA-approved sequencers that is based on semiconductor sequencing technology similar to that of Thermo Fisher's Ion Torrent.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.